The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application notesIHC-P: Use at a concentration of 5 µg/ml.
This antibody gave a positive result in ELISA against the immunizing peptide. Antibody detection limit dilution 1:32,000.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
FunctionInvolved in EGFR signaling.
Tissue specificityIsoform 1 and isoform 2 are co-expressed in placenta, liver, lung, kidney and pancreas. Only isoform 1 is detected in skeletal muscle, brain and heart.
Involvement in diseaseDefects in CCDC50 are the cause of deafness autosomal dominant type 44 (DFNA44) [MIM:607453]. A form of non-syndromic hearing loss. It is initially moderate and affects mainly low to mid frequencies. Later, it progresses to involve all the frequencies and leads to a profound hearing loss by the 6th decade. The onset of the hearing loss occurs in the first decade of life.
Post-translational modificationsPhosphorylated on tyrosine residues.
Cellular localizationCytoplasm. Associated with microtubules of the cytoskeleton and mitotic apparatus.
ab32884 at 5ug/ml staining CCDC50 in human pancreas tissue section by Immunohistochemistry (Formalin/PFA fixed paraffin-embedded sections). Tissue underwent antigen retrieval in steam with citrate buffer (pH 6.0). A AP-staining procedure was used for detection.
References for Anti-CCDC50 antibody (ab32884)
has not yet been referenced specifically in any publications.
Publishing research using ab32884? Please let us know so that we can cite the reference in this datasheet.
Concentration of lot no. is
Concentration not available for this lot.
Find concentration of your lot:
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"